Unicycive Therapeutics reported net income of -$1.75M for the quarter ended Jun 2026. This income statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 1.50M | 1.17M | 1.50M | 1.50M | 1.51M | 1.52M | 1.52M | 1.52M | 3.48M | 2.45M | 3.76M | 4.36M | 9.79M | 6.70M | 11.97M | 14.11M | 20.85M | 15.89M | 25.24M | 27.86M | |||||
| Revenue & cost | |||||||||||||||||||||||||
| Revenue | 0.95M | 0.68M | |||||||||||||||||||||||
| Operating items | |||||||||||||||||||||||||
| Research & DevelopmentR&D | 3.78M | 3.88M | 1.93M | 1.86M | 4.80M | 3.84M | 3.03M | 2.27M | 3.37M | 4.23M | 6.81M | 4.87M | 3.04M | 5.29M | 2.17M | 1.75M | 2.96M | 2.25M | 1.61M | 2.79M | |||||
| Selling, General & AdministrativeSG&A | 0.94M | 1.39M | 1.60M | 1.78M | 1.70M | 1.49M | 1.85M | 2.06M | 2.57M | 2.08M | 2.39M | 2.53M | 3.21M | 3.97M | 5.82M | 5.21M | 4.38M | 4.97M | 6.83M | 7.35M | |||||
| Other Operating ExpensesOther Opex | -2.52M | -0.00M | -10.37M | 0.48M | 1.60M | ||||||||||||||||||||
| Operating ExpensesOpex | 4.71M | 2.75M | 3.54M | 3.64M | 6.50M | 5.33M | 4.88M | 4.32M | 5.94M | 6.31M | 9.20M | 7.40M | 6.25M | 9.26M | 7.99M | 6.96M | 7.34M | 7.22M | 8.44M | 10.14M | |||||
| Operating IncomeOp. Inc | -4.71M | -2.75M | -3.54M | -3.64M | -5.55M | -5.33M | -4.20M | -4.32M | -5.94M | -6.31M | -9.20M | -7.40M | -6.25M | -9.26M | -7.99M | -6.96M | -7.34M | -7.22M | -8.44M | -10.14M | |||||
| EBIT | -4.71M | -2.75M | -3.54M | -3.64M | -5.55M | -5.33M | -4.20M | -4.32M | -5.94M | -6.31M | -9.20M | -7.40M | -6.25M | -9.26M | -7.99M | -6.96M | -7.34M | -7.22M | -8.44M | -10.14M | |||||
| Non-operating items | |||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.06M | 0.00M | 0.00M | 0.01M | 0.03M | 0.02M | 0.02M | 0.02M | 0.02M | 0.01M | 0.02M | 0.01M | 0.01M | 0.01M | 0.03M | ||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.01M | 0.23M | 0.23M | 0.14M | 0.07M | 0.46M | 0.42M | 0.31M | 0.23M | 0.15M | 0.28M | 0.35M | 0.39M | 0.44M | |||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -10.37M | -11.76M | |||||||||||||||||||||||
| Non Operating IncomeNon Op. Inc. | -0.49M | -0.00M | -0.00M | -10.38M | 0.48M | 1.60M | -1.49M | -11.76M | 17.26M | 2.15M | -12.26M | 8.56M | 0.52M | 1.33M | -7.44M | -4.39M | 8.42M | ||||||||
| Net income details | |||||||||||||||||||||||||
| EBT | -4.77M | -2.75M | -3.54M | -3.64M | -5.56M | -5.33M | -4.20M | -4.12M | -5.73M | -6.19M | -9.15M | -6.96M | -5.85M | -8.97M | -7.78M | -6.82M | -7.08M | -6.90M | -8.04M | -9.70M | |||||
| Profit After TaxPAT | -5.20M | -2.75M | -3.54M | -3.64M | -5.56M | -5.33M | -14.57M | -3.84M | -4.41M | -7.80M | -20.96M | 9.86M | -4.10M | -21.52M | 0.57M | -6.45M | -6.01M | -14.67M | -12.82M | -1.75M | |||||
| Income from Non-Controlling InterestsInc. Minority | 6.00M | 17.00M | |||||||||||||||||||||||
| Income from Continuing OperationsIncome (Continuing) | -4.77M | -2.75M | -3.54M | -3.64M | -5.56M | -5.33M | -4.20M | -4.12M | -5.73M | -6.19M | -9.15M | -6.96M | -5.85M | -8.97M | -7.78M | -6.82M | -7.08M | -6.90M | -8.04M | -9.70M | |||||
| Consolidated Net IncomeConsol Net Inc. | -4.77M | -2.75M | -3.54M | -3.64M | -5.56M | -5.33M | -4.20M | -4.12M | -5.73M | -6.19M | -9.15M | -6.96M | -5.85M | -8.97M | -7.78M | -6.82M | -7.08M | -6.90M | -8.04M | -9.70M | |||||
| Income towards Parent CompanyParent Net Inc | -4.77M | -2.75M | -3.54M | -3.64M | -5.56M | -5.33M | -4.20M | -4.12M | -5.73M | -6.19M | -9.15M | -6.96M | -5.85M | -8.97M | -7.78M | -6.82M | -7.08M | -6.90M | -8.04M | -9.70M | |||||
| Preferred Dividend PaymentsPref Dividends | 0.19M | 0.60M | 0.07M | 0.21M | 0.89M | ||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -5.20M | -2.75M | -3.54M | -3.64M | -5.56M | -5.33M | -14.77M | -4.44M | -4.41M | -7.80M | -21.17M | 3.04M | -4.10M | -21.52M | 0.51M | -6.45M | -6.01M | -6.90M | -12.82M | -1.72M | |||||
| Additional items | |||||||||||||||||||||||||
| EPS (Basic) | -3.67 | -2.36 | -2.36 | -2.42 | -3.69 | -3.54 | -9.69 | -2.92 | -1.35 | -3.18 | -6.06 | 0.80 | -0.46 | -3.21 | 0.04 | -0.52 | -0.33 | -0.43 | -0.54 | -0.06 | |||||
| EPS (Diluted) | -3.67 | -2.36 | -2.36 | -2.42 | -3.69 | -3.54 | -9.69 | -2.92 | -1.35 | -3.18 | -6.06 | 0.32 | -0.46 | -3.21 | 0.04 | -0.52 | -0.33 | -0.43 | -0.54 | -0.06 | |||||
| Shares Outstanding | 1.42M | 1.17M | 1.50M | 1.50M | 1.51M | 1.51M | 1.52M | 1.52M | 3.26M | 2.45M | 3.49M | 3.79M | 8.89M | 6.70M | 11.68M | 12.30M | 18.07M | 15.89M | 23.91M | 26.92M | |||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 1.42M | 1.17M | 1.50M | 1.50M | 1.51M | 1.51M | 1.52M | 1.52M | 3.26M | 2.45M | 3.49M | 9.41M | 8.89M | 6.70M | 12.38M | 12.30M | 18.07M | 15.89M | 23.91M | 26.92M | |||||
| EBITDA | -4.71M | -2.75M | -3.54M | -3.64M | -5.55M | -5.33M | -4.20M | -4.32M | -5.94M | -6.31M | -9.20M | -7.40M | -6.25M | -9.26M | -7.99M | -6.96M | -7.34M | -7.22M | -8.44M | -10.14M | |||||
| Interest ExpensesInt Expense | 0.06M | 0.00M | 0.00M | 0.01M | 0.03M | 0.02M | 0.02M | 0.02M | 0.02M | 0.01M | 0.02M | 0.01M | 0.01M | 0.01M | 0.03M |